文献速递消化道肿瘤放疗放疗物理与技术

ATR抑制剂VX-970联合标准治疗改善食管癌疗效的临床前测试

Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.
PubMed 文献 · Radiother Oncol · 2016-11-10

食管癌5年生存率持续偏低,被英国癌症研究中心列为未满足需求的癌症。本研究在食管癌细胞系中评估ATR抑制剂VX-970联合顺铂、卡铂及放疗的疗效,体外实验显示联合治疗增加肿瘤细胞杀伤,体内实验观察到VX-970联合放疗显著延迟肿瘤生长。结论认为VX-970是有效化疗/放疗增敏剂,可融入当前治疗范式,计划开展I期剂量递增安全性研究。

要点

  • VX-970联合顺铂、卡铂或放疗在体外增加食管癌细胞杀伤。
  • 体内实验中VX-970联合放疗显著延迟肿瘤生长。
  • 计划开展VX-970联合放化疗的I期剂量递增安全性研究。

核心结论

  • VX-970是有效的化疗/放疗增敏剂,可融入当前食管癌治疗范式以改善治疗反应。

研究设计与样本

  • 使用食管癌细胞系进行体外和体内临床前研究,评估VX-970联合顺铂、卡铂及放疗的疗效。
  • 放疗实验在模拟肿瘤微环境的缺氧条件下进行。

主要发现

  • VX-970联合顺铂、卡铂和放疗在体外增加肿瘤细胞杀伤。
  • VX-970联合放疗在体内观察到显著的肿瘤生长延迟。

临床怎么用

  • VX-970可作为化疗/放疗增敏剂融入当前食管癌治疗范式。
  • 计划在前瞻性I期剂量递增安全性研究中测试VX-970联合放化疗(EudraCT号:2015-003965-27)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Esophageal cancer has a persistently low 5-year survival rate and has recently been classified as a cancer of unmet need by Cancer Research UK. Consequently, new approaches to therapy are urgently required. Here, we tested the hypothesis that an ATR inhibitor, VX-970, used in combination with standard therapies for esophageal cancer could improve treatment outcome. MATERIAL AND METHODS: Using esophageal cancer cell lines we evaluated the efficacy of combining VX-970 with cisplatin and carboplatin in vitro and with radiation in vitro and in vivo. Radiation experiments were also carried out in hypoxic conditions to mimic the tumor microenvironment. RESULTS: Combining VX-970 with cisplatin, carboplatin and radiation increased tumor cell kill in vitro. A significant tumor growth delay was observed when VX-970 was combined with radiotherapy in vivo. CONCLUSIONS: VX-970 is an effective chemo/radiosensitizer which could be readily integrated in the current treatment paradigm to improve the treatment response in esophageal cancer and we plan to test it prospectively in the forthcoming phase I dose escalation safety study combining the ATR inhibitor VX-970 with chemoradiotherapy in esophageal cancer (EudraCT number: 2015-003965-27).

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Leszczynska KB, Dobrynin G, Leslie RE, et al. Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiother Oncol. 2016. PMID: 27839769. doi:10.1016/j.radonc.2016.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。